GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Other Net Income (Loss)

Solvonis Therapeutics (LSE:SVNS) Other Net Income (Loss) : £-0.16 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Other Net Income (Loss)?

Solvonis Therapeutics's Other Net Income (Loss) for the six months ended in Jun. 2024 was £-0.16 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.16 Mil.

Solvonis Therapeutics's quarterly Other Net Income (Loss) stayed the same from Jun. 2023 (£0.00 Mil) to Dec. 2023 (£0.00 Mil) but then declined from Dec. 2023 (£0.00 Mil) to Jun. 2024 (£-0.16 Mil).

Solvonis Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Solvonis Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Other Net Income (Loss) Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only - - - - -0.16

Solvonis Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Other Net Income (Loss)
Comparable Companies
LSE:SNT LSE:XSG LSE:EQT LSE:INSP LSE:CPH2 XTER:SIE XPAR:SU ETN PH ITW OSTO:ATCO A EMR TSE:7011 CMI AME XTER:ENR OTIS IR BSP:WEGE3 ROK
Traded in Other Exchanges
N/A
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Website
https://www.graftpolymer.com
Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines